Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations 🔗 Access full article via Journal of Allergy and Clinical ImmunologyShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
